IDH1 and glioblastoma: Patients with HGAP generally have shorter overall survival compared to those with conventional pilocytic astrocytomas (CNS WHO grade 1) and IDH-mutant astrocytomas (CNS WHO grade 3), but exhibit better survival outcomes than patients with IDH-wildtype glioblastomas [25, 30].